^
CANCER:

Prostate Cancer

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
No biomarker
Prostate Cancer
enzalutamide capsule
Sensitive
:
A1
FDA - 2 weeks - (New A1)
FOLH1 positive
Prostate Cancer
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
A1
Canada Newswire - 2 weeks - (New A1)
SPOP mutation
Prostate Cancer
Androgen receptor inhibitor
Sensitive
:
C3
Clin Cancer Res - 2 weeks - (New C3)
SPOP mutation
Prostate Cancer
enzalutamide capsule + abiraterone acetate + apalutamide
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
AR wild-type
Prostate Cancer
abiraterone acetate
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
AR wild-type
Prostate Cancer
enzalutamide capsule
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
No biomarker
Prostate Cancer
apalutamide
Sensitive
:
A1
No biomarker
Prostate Cancer
histrelin acetate
Sensitive
:
A1
No biomarker
Prostate Cancer
cabazitaxel
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
olaparib
Sensitive
:
A1
BRCA1 mutation
Prostate Cancer
olaparib
Sensitive
:
A1
No biomarker
Prostate Cancer
relugolix
Sensitive
:
A1
No biomarker
Prostate Cancer
docetaxel + prednisone
Sensitive
:
A1
No biomarker
Prostate Cancer
abiraterone acetate
Sensitive
:
A1
No biomarker
Prostate Cancer
degarelix
Sensitive
:
A1
ATM mutation
Prostate Cancer
olaparib
Sensitive
:
A1
No biomarker
Prostate Cancer
darolutamide
Sensitive
:
A1
BRCA1 mutation
Prostate Cancer
rucaparib
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
rucaparib
Sensitive
:
A1
HRD
Prostate Cancer
olaparib
Sensitive
:
A1
No biomarker
Prostate Cancer
zoledronic acid
Sensitive
:
A1
No biomarker
Prostate Cancer
leuprolide mesylate injectable suspension
Sensitive
:
A1
MSI-H/dMMR
Prostate Cancer
pembrolizumab
Sensitive
:
A2
No biomarker
Prostate Cancer
mitoxantrone
Sensitive
:
A2
No biomarker
Prostate Cancer
etoposide IV
Sensitive
:
A2
No biomarker
Prostate Cancer
atezolizumab
Sensitive
:
A2
No biomarker
Prostate Cancer
docetaxel
Sensitive
:
A2
CDK12 mutation
Prostate Cancer
olaparib
Sensitive
:
A2
PALB2 mutation
Prostate Cancer
olaparib
Sensitive
:
A2
CHEK2 mutation
Prostate Cancer
olaparib
Sensitive
:
A2
CHEK1 mutation
Prostate Cancer
olaparib
Sensitive
:
A2
AR splice variant 7
Prostate Cancer
abiraterone acetate
Resistant
:
A2
AR splice variant 7
Prostate Cancer
enzalutamide capsule
Resistant
:
A2
RAD51B mutation
Prostate Cancer
olaparib
Sensitive
:
A2
RAD51C mutation
Prostate Cancer
olaparib
Sensitive
:
A2
RAD51D mutation
Prostate Cancer
olaparib
Sensitive
:
A2
RAD54L mutation
Prostate Cancer
olaparib
Sensitive
:
A2
FANCL mutation
Prostate Cancer
olaparib
Sensitive
:
A2